Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study
Swain, Sandra M, Dr, Kim, Sung-Bae, MD, Cortés, Javier, MD, Ro, Jungsil, MD, Semiglazov, Vladimir, MD, Campone, Mario, MD, Ciruelos, Eva, MD, Ferrero, Jean-Marc, MD, Schneeweiss, Andreas, MD, Knott, Adam, PhD, Clark, Emma, MSc, Ross, Graham, FFPM, Benyunes, Mark C, MD, Baselga, José, MD
Published in The lancet oncology (01.05.2013)
Published in The lancet oncology (01.05.2013)
Get full text
Journal Article
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Swain, Sandra M, Baselga, José, Kim, Sung-Bae, Ro, Jungsil, Semiglazov, Vladimir, Campone, Mario, Ciruelos, Eva, Ferrero, Jean-Marc, Schneeweiss, Andreas, Heeson, Sarah, Clark, Emma, Ross, Graham, Benyunes, Mark C, Cortés, Javier
Published in The New England journal of medicine (19.02.2015)
Published in The New England journal of medicine (19.02.2015)
Get full text
Journal Article
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Baselga, José, Cortés, Javier, Kim, Sung-Bae, Im, Young-Hyuck, Im, Seock-Ah, Hegg, Roberto, Roman, Laslo, Pedrini, José Luiz, Pienkowski, Tadeusz, Knott, Adam, Clark, Emma, Benyunes, Mark C, Ross, Graham, Swain, Sandra M
Published in The New England journal of medicine (12.01.2012)
Published in The New England journal of medicine (12.01.2012)
Get full text
Journal Article
Cardiac Tolerability of Pertuzumab Plus Trastuzumab Plus Docetaxel in Patients With HER2‐Positive Metastatic Breast Cancer in CLEOPATRA: A Randomized, Double‐Blind, Placebo‐Controlled Phase III Study
Swain, Sandra M., Ewer, Michael S., Cortés, Javier, Amadori, Dino, Miles, David, Knott, Adam, Clark, Emma, Benyunes, Mark C., Ross, Graham, Baselga, José
Published in The oncologist (Dayton, Ohio) (01.03.2013)
Published in The oncologist (Dayton, Ohio) (01.03.2013)
Get full text
Journal Article
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Swain, Sandra M., Baselga, José, Kim, Sung-Bae, Ro, Jungsil, Semiglazov, Vladimir, Campone, Mario, Ciruelos, Eva, Ferrero, Jean-Marc, Schneeweiss, Andreas, Heeson, Sarah, Clark, Emma, Ross, Graham, Benyunes, Mark C., Cortés, Javier
Published in The New England journal of medicine (19.02.2015)
Published in The New England journal of medicine (19.02.2015)
Get full text
Journal Article
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Baselga, José, Cortés, Javier, Kim, Sung-Bae, Im, Seock-Ah, Hegg, Roberto, Im, Young-Hyuck, Roman, Laslo, Pedrini, José Luiz, Pienkowski, Tadeusz, Knott, Adam, Clark, Emma, Benyunes, Mark C., Ross, Graham, Swain, Sandra M.
Published in The New England journal of medicine (12.01.2012)
Published in The New England journal of medicine (12.01.2012)
Get full text
Journal Article
Pharmacokinetic and exposure–response analyses of pertuzumab in combination with trastuzumab and docetaxel during neoadjuvant treatment of HER2+ early breast cancer
Quartino, Angelica L., Li, Hanbin, Jin, Jin Y., Wada, D. Russell, Benyunes, Mark C., McNally, Virginia, Viganò, Lucia, Nijem, Ihsan, Lum, Bert L., Garg, Amit
Published in Cancer chemotherapy and pharmacology (01.02.2017)
Published in Cancer chemotherapy and pharmacology (01.02.2017)
Get full text
Journal Article
Neutropenia in Patients Treated with Rituximab
Voog, Eric, Morschhauser, Franck, Solal-Céligny, Philippe
Published in The New England journal of medicine (26.06.2003)
Published in The New England journal of medicine (26.06.2003)
Get full text
Journal Article
Interstitial Pneumonitis Related to Rituximab Therapy
Burton, Catherine, Kaczmarski, Richard, Jan-Mohamed, Riaz
Published in The New England journal of medicine (26.06.2003)
Published in The New England journal of medicine (26.06.2003)
Get full text
Journal Article
HER2 USES FOR AND ARTICLE OF MANUFACTURE INCLUDING HER2 DIMERIZATION INHIBITOR PERTUZUMAB
AMLER LUKAS C, RATNAYAKE JAYANTHA, CLARK EMMA L, KWONG GLOVER ZEPHANIA W, ALAVATTAM SREEDHARA, ROSS GRAHAM A, BENYUNES MARK C, DE TOLEDO PELIZON CHRISTINA H, MITCHELL LADA, WALKER RU AMIR
Year of Publication 10.07.2024
Get full text
Year of Publication 10.07.2024
Patent
HER2 USES FOR AND ARTICLE OF MANUFACTURE INCLUDING HER2 DIMERIZATION INHIBITOR PERTUZUMAB
AMLER LUKAS C, RATNAYAKE JAYANTHA, CLARK EMMA L, KWONG GLOVER ZEPHANIA W, ALAVATTAM SREEDHARA, ROSS GRAHAM A, BENYUNES MARK C, DE TOLEDO PELIZON CHRISTINA H, MITCHELL LADA, WALKER RU AMIR
Year of Publication 25.05.2023
Get full text
Year of Publication 25.05.2023
Patent
HER2 USES FOR AND ARTICLE OF MANUFACTURE INCLUDING HER2 DIMERIZATION INHIBITOR PERTUZUMAB
AMLER LUKAS C, RATNAYAKE JAYANTHA, CLARK EMMA L, KWONG GLOVER ZEPHANIA W, ALAVATTAM SREEDHARA, ROSS GRAHAM A, BENYUNES MARK C, DE TOLEDO PELIZON CHRISTINA H, MITCHELL LADA, WALKER RU AMIR
Year of Publication 28.02.2023
Get full text
Year of Publication 28.02.2023
Patent
HER2 USES FOR AND ARTICLE OF MANUFACTURE INCLUDING HER2 DIMERIZATION INHIBITOR PERTUZUMAB
AMLER LUKAS C, RATNAYAKE JAYANTHA, CLARK EMMA L, KWONG GLOVER ZEPHANIA W, ALAVATTAM SREEDHARA, ROSS GRAHAM A, BENYUNES MARK C, DE TOLEDO PELIZON CHRISTINA H, MITCHELL LADA, WALKER RU AMIR
Year of Publication 02.03.2017
Get full text
Year of Publication 02.03.2017
Patent
USES FOR AND ARTICLE OF MANUFACTURE INCLUDING HER2 DIMERIZATION INHIBITOR PERTUZUMAB
AMLER LUKAS C, RATNAYAKE JAYANTHA, CLARK EMMA L, KWONG GLOVER ZEPHANIA W, ALAVATTAM SREEDHARA, ROSS GRAHAM A, BENYUNES MARK C, DE TOLEDO PELIZON CHRISTINA H, MITCHELL LADA, WALKER RU AMIR
Year of Publication 19.06.2014
Get full text
Year of Publication 19.06.2014
Patent
Overall survival benefit with pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer in CLEOPATRA, a randomised Phase 3 study
Swain, Sandra M., Kim, Sung-Bae, Cortés, Javier, Ro, Jungsil, Semiglazov, Vladimir, Campone, Mario, Ciruelos, Eva, Ferrero, Jean-Marc, Schneeweiss, Andreas, Knott, Adam, Clark, Emma, Ross, Graham, Benyunes, Mark C., Baselga, José
Published in The lancet oncology (18.04.2013)
Published in The lancet oncology (18.04.2013)
Get full text
Journal Article